Gal-1 (Galectin-1) Upregulation Contributes to Abdominal Aortic Aneurysm Progression by Enhancing Vascular Inflammation

OBJECTIVE:Abdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless, no prognostic and therapeutic target is available for disease management. Gal-1 (galectin-1) is a β-galactoside–binding lectin constitutivel...

Full description

Saved in:
Bibliographic Details
Published inArteriosclerosis, thrombosis, and vascular biology Vol. 41; no. 1; pp. 331 - 345
Main Authors Chiang, Ming-Tsai, Chen, I-Ming, Hsu, Fu-Fei, Chen, Yen-Hui, Tsai, Min-Shao, Hsu, Yaw-Wen, Leu, Hsin-Bang, Huang, Po-Hsun, Chen, Jaw-Wen, Liu, Fu-Tong, Chen, Ying-Hwa, Chau, Lee-Young
Format Journal Article
LanguageEnglish
Published United States Lippincott Williams & Wilkins 01.01.2021
American Heart Association, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract OBJECTIVE:Abdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless, no prognostic and therapeutic target is available for disease management. Gal-1 (galectin-1) is a β-galactoside–binding lectin constitutively expressed in vasculature with roles in maintaining vascular homeostasis. This study aims to investigate the potential involvement of Gal-1 in AAA progression. APPROACH AND RESULTS:Gal-1 was significantly elevated in circulation and aortic tissues of Ang II (angiotensin II)–infused apoE-deficient mice developing AAA. Gal-1 deficiency reduced incidence and severity of AAA with lower expression of aortic MMPs (matrix metalloproteases) and proinflammatory cytokines. TNFα (tumor necrosis factor alpha) induced Gal-1 expression in cultured vascular smooth muscle cells and adventitial fibroblasts. Gal-1 deletion enhanced TNFα-induced MMP9 expression in fibroblasts but not vascular smooth muscle cells. Cysteinyl-labeling assay demonstrated that aortic Gal-1 exhibited susceptibility to oxidation in vivo. Recombinant oxidized Gal-1 induced expression of MMP9 and inflammatory cytokines to various extents in macrophages, vascular smooth muscle cells, and fibroblasts through activation of MAP kinase signaling. Clinically, serum MMP9 level was significantly higher in both patients with AAA and coronary artery disease than in control subjects, whereas serum Gal-1 level was elevated in patients with AAA but not coronary artery disease when compared with controls. CONCLUSIONS:Gal-1 is highly induced and contributes to AAA by enhancing matrix degradation activity and inflammatory responses in experimental model. The pathological link between Gal-1 and AAA is also observed in human patients. These findings support the potential of Gal-1 as a disease biomarker and therapeutic target of AAA.
AbstractList Abdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless, no prognostic and therapeutic target is available for disease management. Gal-1 (galectin-1) is a β-galactoside-binding lectin constitutively expressed in vasculature with roles in maintaining vascular homeostasis. This study aims to investigate the potential involvement of Gal-1 in AAA progression. Approach and Results: Gal-1 was significantly elevated in circulation and aortic tissues of Ang II (angiotensin II)-infused apoE-deficient mice developing AAA. Gal-1 deficiency reduced incidence and severity of AAA with lower expression of aortic MMPs (matrix metalloproteases) and proinflammatory cytokines. TNFα (tumor necrosis factor alpha) induced Gal-1 expression in cultured vascular smooth muscle cells and adventitial fibroblasts. Gal-1 deletion enhanced TNFα-induced MMP9 expression in fibroblasts but not vascular smooth muscle cells. Cysteinyl-labeling assay demonstrated that aortic Gal-1 exhibited susceptibility to oxidation in vivo. Recombinant oxidized Gal-1 induced expression of MMP9 and inflammatory cytokines to various extents in macrophages, vascular smooth muscle cells, and fibroblasts through activation of MAP (mitogen-activated protein) kinase signaling. Clinically, serum MMP9 level was significantly higher in both patients with AAA and coronary artery disease than in control subjects, whereas serum Gal-1 level was elevated in patients with AAA but not coronary artery disease when compared with controls.OBJECTIVEAbdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless, no prognostic and therapeutic target is available for disease management. Gal-1 (galectin-1) is a β-galactoside-binding lectin constitutively expressed in vasculature with roles in maintaining vascular homeostasis. This study aims to investigate the potential involvement of Gal-1 in AAA progression. Approach and Results: Gal-1 was significantly elevated in circulation and aortic tissues of Ang II (angiotensin II)-infused apoE-deficient mice developing AAA. Gal-1 deficiency reduced incidence and severity of AAA with lower expression of aortic MMPs (matrix metalloproteases) and proinflammatory cytokines. TNFα (tumor necrosis factor alpha) induced Gal-1 expression in cultured vascular smooth muscle cells and adventitial fibroblasts. Gal-1 deletion enhanced TNFα-induced MMP9 expression in fibroblasts but not vascular smooth muscle cells. Cysteinyl-labeling assay demonstrated that aortic Gal-1 exhibited susceptibility to oxidation in vivo. Recombinant oxidized Gal-1 induced expression of MMP9 and inflammatory cytokines to various extents in macrophages, vascular smooth muscle cells, and fibroblasts through activation of MAP (mitogen-activated protein) kinase signaling. Clinically, serum MMP9 level was significantly higher in both patients with AAA and coronary artery disease than in control subjects, whereas serum Gal-1 level was elevated in patients with AAA but not coronary artery disease when compared with controls.Gal-1 is highly induced and contributes to AAA by enhancing matrix degradation activity and inflammatory responses in experimental model. The pathological link between Gal-1 and AAA is also observed in human patients. These findings support the potential of Gal-1 as a disease biomarker and therapeutic target of AAA.CONCLUSIONSGal-1 is highly induced and contributes to AAA by enhancing matrix degradation activity and inflammatory responses in experimental model. The pathological link between Gal-1 and AAA is also observed in human patients. These findings support the potential of Gal-1 as a disease biomarker and therapeutic target of AAA.
Abdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless, no prognostic and therapeutic target is available for disease management. Gal-1 (galectin-1) is a β-galactoside-binding lectin constitutively expressed in vasculature with roles in maintaining vascular homeostasis. This study aims to investigate the potential involvement of Gal-1 in AAA progression. Approach and Results: Gal-1 was significantly elevated in circulation and aortic tissues of Ang II (angiotensin II)-infused apoE-deficient mice developing AAA. Gal-1 deficiency reduced incidence and severity of AAA with lower expression of aortic MMPs (matrix metalloproteases) and proinflammatory cytokines. TNFα (tumor necrosis factor alpha) induced Gal-1 expression in cultured vascular smooth muscle cells and adventitial fibroblasts. Gal-1 deletion enhanced TNFα-induced MMP9 expression in fibroblasts but not vascular smooth muscle cells. Cysteinyl-labeling assay demonstrated that aortic Gal-1 exhibited susceptibility to oxidation in vivo. Recombinant oxidized Gal-1 induced expression of MMP9 and inflammatory cytokines to various extents in macrophages, vascular smooth muscle cells, and fibroblasts through activation of MAP (mitogen-activated protein) kinase signaling. Clinically, serum MMP9 level was significantly higher in both patients with AAA and coronary artery disease than in control subjects, whereas serum Gal-1 level was elevated in patients with AAA but not coronary artery disease when compared with controls. Gal-1 is highly induced and contributes to AAA by enhancing matrix degradation activity and inflammatory responses in experimental model. The pathological link between Gal-1 and AAA is also observed in human patients. These findings support the potential of Gal-1 as a disease biomarker and therapeutic target of AAA.
OBJECTIVE:Abdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless, no prognostic and therapeutic target is available for disease management. Gal-1 (galectin-1) is a β-galactoside–binding lectin constitutively expressed in vasculature with roles in maintaining vascular homeostasis. This study aims to investigate the potential involvement of Gal-1 in AAA progression. APPROACH AND RESULTS:Gal-1 was significantly elevated in circulation and aortic tissues of Ang II (angiotensin II)–infused apoE-deficient mice developing AAA. Gal-1 deficiency reduced incidence and severity of AAA with lower expression of aortic MMPs (matrix metalloproteases) and proinflammatory cytokines. TNFα (tumor necrosis factor alpha) induced Gal-1 expression in cultured vascular smooth muscle cells and adventitial fibroblasts. Gal-1 deletion enhanced TNFα-induced MMP9 expression in fibroblasts but not vascular smooth muscle cells. Cysteinyl-labeling assay demonstrated that aortic Gal-1 exhibited susceptibility to oxidation in vivo. Recombinant oxidized Gal-1 induced expression of MMP9 and inflammatory cytokines to various extents in macrophages, vascular smooth muscle cells, and fibroblasts through activation of MAP kinase signaling. Clinically, serum MMP9 level was significantly higher in both patients with AAA and coronary artery disease than in control subjects, whereas serum Gal-1 level was elevated in patients with AAA but not coronary artery disease when compared with controls. CONCLUSIONS:Gal-1 is highly induced and contributes to AAA by enhancing matrix degradation activity and inflammatory responses in experimental model. The pathological link between Gal-1 and AAA is also observed in human patients. These findings support the potential of Gal-1 as a disease biomarker and therapeutic target of AAA.
Author Chiang, Ming-Tsai
Chen, Yen-Hui
Hsu, Fu-Fei
Chau, Lee-Young
Tsai, Min-Shao
Huang, Po-Hsun
Liu, Fu-Tong
Chen, I-Ming
Hsu, Yaw-Wen
Chen, Ying-Hwa
Chen, Jaw-Wen
Leu, Hsin-Bang
AuthorAffiliation Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.)
Division of Cardiovascular Surgery, Department of Surgery (I.-M.C.), Taipei Veterans General Hospital, Taiwan
AuthorAffiliation_xml – name: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.)
– name: Division of Cardiovascular Surgery, Department of Surgery (I.-M.C.), Taipei Veterans General Hospital, Taiwan
– name: Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.). Division of Cardiovascular Surgery, Department of Surgery, National Yang-Ming University, Taipei, Taiwan. (I.-M.C.) Division of Healthcare and Management, Healthcare Center, National Yang-Ming University, Taipei, Taiwan. (H.-B.L.) Division of Cardiology, Department of Internal Medicine, National Yang-Ming University, Taipei, Taiwan. (P.-H.H., J.-W.C., Ying-Hwa Chen) Taipei Veterans General Hospital, Taiwan. School of Medicine, National Yang-Ming University, Taipei, Taiwan. (H.-B.L., Ying-Hwa Chen) Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. (P.-H.H.) Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan. (J.-W.C.)
Author_xml – sequence: 1
  givenname: Ming-Tsai
  surname: Chiang
  fullname: Chiang, Ming-Tsai
  organization: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.)
– sequence: 2
  givenname: I-Ming
  surname: Chen
  fullname: Chen, I-Ming
  organization: Division of Cardiovascular Surgery, Department of Surgery (I.-M.C.), Taipei Veterans General Hospital, Taiwan
– sequence: 3
  givenname: Fu-Fei
  surname: Hsu
  fullname: Hsu, Fu-Fei
  organization: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.)
– sequence: 4
  givenname: Yen-Hui
  surname: Chen
  fullname: Chen, Yen-Hui
  organization: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.)
– sequence: 5
  givenname: Min-Shao
  surname: Tsai
  fullname: Tsai, Min-Shao
  organization: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.)
– sequence: 6
  givenname: Yaw-Wen
  surname: Hsu
  fullname: Hsu, Yaw-Wen
  organization: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.)
– sequence: 7
  givenname: Hsin-Bang
  surname: Leu
  fullname: Leu, Hsin-Bang
  organization: Division of Healthcare and Management, Healthcare Center (H.-B.L.), Taipei Veterans General Hospital, Taiwan
– sequence: 8
  givenname: Po-Hsun
  surname: Huang
  fullname: Huang, Po-Hsun
  organization: Division of Cardiology, Department of Internal Medicine (P.-H.H., J.-W.C., Ying-Hwa Chen), Taipei Veterans General Hospital, Taiwan
– sequence: 9
  givenname: Jaw-Wen
  surname: Chen
  fullname: Chen, Jaw-Wen
  organization: Division of Cardiology, Department of Internal Medicine (P.-H.H., J.-W.C., Ying-Hwa Chen), Taipei Veterans General Hospital, Taiwan
– sequence: 10
  givenname: Fu-Tong
  surname: Liu
  fullname: Liu, Fu-Tong
  organization: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.)
– sequence: 11
  givenname: Ying-Hwa
  surname: Chen
  fullname: Chen, Ying-Hwa
  organization: Division of Cardiology, Department of Internal Medicine (P.-H.H., J.-W.C., Ying-Hwa Chen), Taipei Veterans General Hospital, Taiwan
– sequence: 12
  givenname: Lee-Young
  surname: Chau
  fullname: Chau, Lee-Young
  organization: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.)
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33147994$$D View this record in MEDLINE/PubMed
BookMark eNp9kktvGyEUhVGVqnm0f6CLimW6wOExzGM5tdIkUqR0kWSLGGBsWgZcYGT53xfHzqYLL7iXK53vSJfDJTjzwRsAvhK8IKQmN_3z64_-vl8QiheMcNa1H8AF4bRCVc3qs3LHTYd4XdFzcJnSb4xxRSn-BM4ZI1XTddUF2N5Jhwi8Ls2obD0i3-HLJprV7GS2wcNl8DnaYc4mwRxgP-gwWS8d7EPMVsHemznu0gR_xbCKJqU9NOzgrV9Lr6xfwVeZVHGL8MGPTk7Tm-9n8HGULpkvx34FXn7ePi_v0ePT3cOyf0SKdbxFQ6M6rTUeOFej1JI2StW6aUZMZdsqiluuTDsUyUiNxpqolqhSR0X0oCRjV-D64LuJ4e9sUhaTTco4J70JcxK04k1XNx3vivTbUToPk9FiE-0k4068P1YRtAeBiiGlaEahbH7bJkdpnSBY7HMRx1xEyUUcciko_Q99dz8J1QdoG1w2Mf1x89ZEsTbS5fVpsDoB7r8BqzFHFFOCSRlROYyyf8mns8c
CitedBy_id crossref_primary_10_1096_fj_202301832RR
crossref_primary_10_3390_biom12020339
crossref_primary_10_4196_kjpp_2022_26_5_347
crossref_primary_10_1016_j_autrev_2022_103258
crossref_primary_10_1080_15384101_2022_2124489
crossref_primary_10_12998_wjcc_v12_i21_4717
crossref_primary_10_1042_BST20200677
crossref_primary_10_1038_s41392_023_01325_7
crossref_primary_10_1111_jcmm_16757
crossref_primary_10_3389_fcvm_2021_753095
crossref_primary_10_1016_j_mvr_2024_104754
crossref_primary_10_1080_15384101_2022_2094577
crossref_primary_10_3390_diagnostics12010183
crossref_primary_10_1002_smll_202402141
crossref_primary_10_1016_j_jep_2021_114845
crossref_primary_10_2174_011573403X274886231227111902
crossref_primary_10_1126_sciadv_abm7322
crossref_primary_10_1097_CD9_0000000000000097
crossref_primary_10_1155_2022_4766987
Cites_doi 10.1073/pnas.1609019113
10.1161/01.ATV.0000143384.69170.2d
10.1371/journal.pone.0001774
10.1073/pnas.0603883103
10.1016/j.ajpath.2012.09.022
10.1042/CS20030189
10.1093/glycob/cwu008
10.4049/jimmunol.0803164
10.1016/S0021-9258(19)50024-2
10.1161/01.atv.20.12.2527
10.1161/ATVBAHA.110.206573
10.1016/s0304-4165(02)00313-6
10.1523/JNEUROSCI.4483-03.2004
10.4049/jimmunol.1701172
10.1111/febs.13634
10.1016/j.jvs.2006.04.047
10.1159/000025625
10.1038/s41598-018-29843-3
10.1007/BF02978209
10.1101/cshperspect.a011254
10.1038/sj.onc.1204950
10.3389/fphar.2010.00009
10.1152/ajplung.00192.2006
10.1016/j.imlet.2010.03.010
10.1172/JCI38308
10.1016/j.biopha.2009.09.008
10.1161/CIRCRESAHA.112.270520
10.1126/science.6367039
10.1016/j.jtcvs.2011.07.053
10.1074/jbc.M205698200
10.1016/s1471-4906(02)02232-9
10.1161/01.ATV.0000085631.76095.64
10.1161/01.CIR.0000058700.41738.12
10.1016/j.ejvs.2005.10.030
10.1046/j.1432-1033.2000.01311.x
10.1093/glycob/cwl025
10.1146/annurev-med-101712-174206
10.1038/s41598-018-22135-w
10.1161/01.ATV.0000214999.12921.4f
10.1165/ajrcmb.23.1.4014
10.1016/s0008-6363(99)00276-x
10.1165/ajrcmb.20.4.3420
10.1056/NEJMcp1401430
10.1038/nrcardio.2017.52
10.1291/hypres.30.1015
10.1161/01.CIR.0000165117.71483.0C
ContentType Journal Article
Copyright Lippincott Williams & Wilkins
2020 American Heart Association, Inc.
Copyright_xml – notice: Lippincott Williams & Wilkins
– notice: 2020 American Heart Association, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1161/ATVBAHA.120.315398
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1524-4636
EndPage 345
ExternalDocumentID 33147994
10_1161_ATVBAHA_120_315398
10.1161/ATVBAHA.120.315398
00043605-202101000-00032
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.Z2
01R
0R~
1J1
23N
2WC
40H
4Q1
4Q2
4Q3
5GY
5RE
5VS
77Y
7O~
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AAXQO
ABASU
ABBUW
ABDIG
ABJNI
ABPXF
ABQRW
ABVCZ
ABXVJ
ABZAD
ABZZY
ACDDN
ACEWG
ACGFS
ACGOD
ACILI
ACLDA
ACPRK
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADBBV
ADGGA
ADHPY
AE6
AENEX
AFBFQ
AFDTB
AFUWQ
AGINI
AHMBA
AHOMT
AHQNM
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
AYCSE
BAWUL
BOYCO
BQLVK
C45
CS3
DIK
DIWNM
E.X
E3Z
EBS
EEVPB
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FRP
GNXGY
GQDEL
GX1
H0~
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
JK3
JK8
K8S
KD2
KMI
KQ8
L-C
L7B
N9A
N~7
N~B
O9-
OAG
OAH
OB2
OL1
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
OVD
OVDNE
OVIDH
OVLEI
OWW
OWY
OXXIT
P2P
PQQKQ
PZZ
RAH
RIG
RLZ
S4R
S4S
TEORI
TR2
TSPGW
V2I
VVN
W3M
W8F
WOQ
WOW
X3V
X3W
YFH
.3C
.55
.GJ
3O-
53G
71W
AAYXX
ACCJW
ADFPA
ADGHP
ADNKB
AE3
AEETU
AFFNX
AHJKT
AHRYX
AJNYG
BS7
C1A
CITATION
DUNZO
EJD
FW0
H13
J5H
JF9
JG8
N~M
OCUKA
ODA
ORVUJ
OUVQU
OWU
OWV
OWX
OWZ
P-K
T8P
X7M
XXN
XYM
ZGI
ZZMQN
ACIJW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c3958-b7c9ddd0b55cfada27cc6d77f02a88c2085ce8bdddf2ed0d1c81cd1cfc1dbca33
ISSN 1079-5642
1524-4636
IngestDate Thu Jul 10 20:02:29 EDT 2025
Thu Apr 03 07:06:48 EDT 2025
Tue Jul 01 00:38:34 EDT 2025
Thu Apr 24 23:10:21 EDT 2025
Fri May 16 03:49:46 EDT 2025
Fri May 16 03:51:37 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords matrix metalloprotease
galectin 1
aorta
cytokines
incidence
aortic aneurysm, abdominal
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3958-b7c9ddd0b55cfada27cc6d77f02a88c2085ce8bdddf2ed0d1c81cd1cfc1dbca33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-7414-6358
0000-0001-6832-3234
0000-0002-6316-2328
PMID 33147994
PQID 2457967959
PQPubID 23479
PageCount 15
ParticipantIDs proquest_miscellaneous_2457967959
pubmed_primary_33147994
crossref_citationtrail_10_1161_ATVBAHA_120_315398
crossref_primary_10_1161_ATVBAHA_120_315398
wolterskluwer_health_10_1161_ATVBAHA_120_315398
wolterskluwer_health_00043605-202101000-00032
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-January-01
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-January-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Arteriosclerosis, thrombosis, and vascular biology
PublicationTitleAlternate Arterioscler Thromb Vasc Biol
PublicationYear 2021
Publisher Lippincott Williams & Wilkins
American Heart Association, Inc
Publisher_xml – name: Lippincott Williams & Wilkins
– name: American Heart Association, Inc
References e_1_3_4_3_2
e_1_3_4_2_2
e_1_3_4_9_2
e_1_3_4_8_2
e_1_3_4_7_2
e_1_3_4_41_2
e_1_3_4_6_2
e_1_3_4_40_2
e_1_3_4_5_2
e_1_3_4_4_2
e_1_3_4_22_2
e_1_3_4_45_2
e_1_3_4_23_2
e_1_3_4_44_2
e_1_3_4_20_2
e_1_3_4_43_2
e_1_3_4_21_2
e_1_3_4_42_2
e_1_3_4_26_2
e_1_3_4_27_2
e_1_3_4_48_2
e_1_3_4_24_2
e_1_3_4_47_2
e_1_3_4_25_2
e_1_3_4_46_2
e_1_3_4_28_2
e_1_3_4_29_2
Cummings RD (e_1_3_4_14_2) 2009
e_1_3_4_30_2
e_1_3_4_11_2
e_1_3_4_34_2
e_1_3_4_12_2
e_1_3_4_33_2
e_1_3_4_32_2
e_1_3_4_10_2
e_1_3_4_31_2
e_1_3_4_15_2
e_1_3_4_38_2
e_1_3_4_16_2
e_1_3_4_37_2
e_1_3_4_13_2
e_1_3_4_36_2
e_1_3_4_35_2
e_1_3_4_19_2
e_1_3_4_17_2
e_1_3_4_18_2
e_1_3_4_39_2
References_xml – ident: e_1_3_4_38_2
  doi: 10.1073/pnas.1609019113
– ident: e_1_3_4_8_2
  doi: 10.1161/01.ATV.0000143384.69170.2d
– ident: e_1_3_4_46_2
  doi: 10.1371/journal.pone.0001774
– ident: e_1_3_4_25_2
  doi: 10.1073/pnas.0603883103
– ident: e_1_3_4_39_2
  doi: 10.1016/j.ajpath.2012.09.022
– ident: e_1_3_4_12_2
  doi: 10.1042/CS20030189
– ident: e_1_3_4_19_2
  doi: 10.1093/glycob/cwu008
– ident: e_1_3_4_13_2
  doi: 10.4049/jimmunol.0803164
– ident: e_1_3_4_17_2
  doi: 10.1016/S0021-9258(19)50024-2
– ident: e_1_3_4_32_2
  doi: 10.1161/01.atv.20.12.2527
– ident: e_1_3_4_48_2
  doi: 10.1161/ATVBAHA.110.206573
– ident: e_1_3_4_15_2
  doi: 10.1016/s0304-4165(02)00313-6
– ident: e_1_3_4_22_2
  doi: 10.1523/JNEUROSCI.4483-03.2004
– ident: e_1_3_4_21_2
  doi: 10.4049/jimmunol.1701172
– ident: e_1_3_4_4_2
  doi: 10.1111/febs.13634
– ident: e_1_3_4_30_2
  doi: 10.1016/j.jvs.2006.04.047
– ident: e_1_3_4_26_2
  doi: 10.1159/000025625
– ident: e_1_3_4_28_2
  doi: 10.1038/s41598-018-29843-3
– ident: e_1_3_4_33_2
  doi: 10.1007/BF02978209
– ident: e_1_3_4_44_2
  doi: 10.1101/cshperspect.a011254
– ident: e_1_3_4_42_2
  doi: 10.1038/sj.onc.1204950
– ident: e_1_3_4_31_2
  doi: 10.3389/fphar.2010.00009
– ident: e_1_3_4_40_2
  doi: 10.1152/ajplung.00192.2006
– ident: e_1_3_4_23_2
  doi: 10.1016/j.imlet.2010.03.010
– ident: e_1_3_4_9_2
  doi: 10.1172/JCI38308
– ident: e_1_3_4_47_2
  doi: 10.1016/j.biopha.2009.09.008
– ident: e_1_3_4_11_2
  doi: 10.1161/CIRCRESAHA.112.270520
– ident: e_1_3_4_24_2
  doi: 10.1126/science.6367039
– ident: e_1_3_4_10_2
  doi: 10.1016/j.jtcvs.2011.07.053
– ident: e_1_3_4_43_2
  doi: 10.1074/jbc.M205698200
– ident: e_1_3_4_20_2
  doi: 10.1016/s1471-4906(02)02232-9
– volume-title: In: Essentials of Glycobiology
  year: 2009
  ident: e_1_3_4_14_2
– ident: e_1_3_4_29_2
  doi: 10.1161/01.ATV.0000085631.76095.64
– ident: e_1_3_4_45_2
  doi: 10.1161/01.CIR.0000058700.41738.12
– ident: e_1_3_4_5_2
  doi: 10.1016/j.ejvs.2005.10.030
– ident: e_1_3_4_18_2
  doi: 10.1046/j.1432-1033.2000.01311.x
– ident: e_1_3_4_16_2
  doi: 10.1093/glycob/cwl025
– ident: e_1_3_4_3_2
  doi: 10.1146/annurev-med-101712-174206
– ident: e_1_3_4_41_2
  doi: 10.1038/s41598-018-22135-w
– ident: e_1_3_4_6_2
  doi: 10.1161/01.ATV.0000214999.12921.4f
– ident: e_1_3_4_34_2
  doi: 10.1165/ajrcmb.23.1.4014
– ident: e_1_3_4_27_2
  doi: 10.1016/s0008-6363(99)00276-x
– ident: e_1_3_4_35_2
  doi: 10.1165/ajrcmb.20.4.3420
– ident: e_1_3_4_2_2
  doi: 10.1056/NEJMcp1401430
– ident: e_1_3_4_7_2
  doi: 10.1038/nrcardio.2017.52
– ident: e_1_3_4_37_2
  doi: 10.1291/hypres.30.1015
– ident: e_1_3_4_36_2
  doi: 10.1161/01.CIR.0000165117.71483.0C
SSID ssj0004220
Score 2.4516435
Snippet OBJECTIVE:Abdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless,...
Abdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless, no...
SourceID proquest
pubmed
crossref
wolterskluwer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 331
SubjectTerms Adventitia - metabolism
Adventitia - pathology
Angiotensin II
Animals
Aorta, Abdominal - metabolism
Aorta, Abdominal - pathology
Aortic Aneurysm, Abdominal - chemically induced
Aortic Aneurysm, Abdominal - metabolism
Aortic Aneurysm, Abdominal - pathology
Aortitis - chemically induced
Aortitis - metabolism
Aortitis - pathology
Case-Control Studies
Cells, Cultured
Cytokines - metabolism
Disease Models, Animal
Disease Progression
Extracellular Matrix - metabolism
Extracellular Matrix - pathology
Fibroblasts - metabolism
Fibroblasts - pathology
Galectin 1 - blood
Galectin 1 - deficiency
Galectin 1 - genetics
Galectin 1 - metabolism
Humans
Inflammation Mediators - metabolism
Macrophages, Peritoneal - metabolism
Macrophages, Peritoneal - pathology
Male
Matrix Metalloproteinase 9 - metabolism
Mice
Mice, Inbred C57BL
Mice, Knockout, ApoE
Mitogen-Activated Protein Kinases - metabolism
Muscle, Smooth, Vascular - metabolism
Muscle, Smooth, Vascular - pathology
Myocytes, Smooth Muscle - metabolism
Myocytes, Smooth Muscle - pathology
Signal Transduction
Up-Regulation
Vascular Remodeling
Title Gal-1 (Galectin-1) Upregulation Contributes to Abdominal Aortic Aneurysm Progression by Enhancing Vascular Inflammation
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00043605-202101000-00032
https://www.ncbi.nlm.nih.gov/pubmed/33147994
https://www.proquest.com/docview/2457967959
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAIIe4rNxmJB1DlLc49jwFtdKAiIbXTeIoc2xnV1mRaGk3jh_B7OSdO0mwdE-MlalPHdft9iX2Oz_kOIe88JVylbMlkxhVzgRVMSIFRVq6MbDA5dJ1IO_nmj2fulwPvYDD43Ytaqpbplvx1ZV7J_6AK5wBXzJK9AbJdp3ACXgO-cASE4fhPGH8Wx4zXhr5A7_s8Zxyt_NnJqakwj9Ci_FRd1MpoOcSpKkwdr7jADkcxKlqelwtMGTg0QbE5rkl38p8oxZEfjvbbYNW9PAP-LFZYduq1KPhclDA6mHONaAGWX1ik7Tv0zncxr43u0yqwYN74rCfwbWxaivnqI_NQ3GOTdoZFBpZVveSu2K5ea_pD52xczfvODJtfcmZ0u1RjuM2XfYauRYaC2RoxzzfSXOvzgI_zQDzd_xiP0d-LvgnPMfWuL-lrX9f8Frltg_mBlTG-fu-p0Nu2UblohtAmY_l8e72PiwueNSvmHrl_VmBgRHlU50X0VjfTh-RBY5bQ2HDsERno_DG5M2kCL56Qs5pq9P2KaB9on2a0RzO6LGhHM2poRlua0R7NaHpOO5rRlma0T7OnZLa7M_00Zk3NDiadyAtZGshIKWWlniczoYQdSOmrIMgsW4ShxIqwUocpNMlsrSzFZcglHDPJVSqF4zwjG3mR601CIx8Wr1L7ViosN8iC0MqUllrUJoP27CHh7R-byEbQHuuqHCe1YevzpAEjATASA8aQjLprToycy7Wt37Z4JfDUxa00keuiKhPbxRzuIPKiIXlugOz6cxzuBlHkDgm7gGxiMpuTevfdtzyGN4DFG2kHB37P9pXt_z6-Fze-4iW5u7rtXpGN5WmlX8Oqepm-qSn-B1Y1yQw
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gal-1+%28Galectin-1%29+Upregulation+Contributes+to+Abdominal+Aortic+Aneurysm+Progression+by+Enhancing+Vascular+Inflammation&rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&rft.au=Chiang%2C+Ming-Tsai&rft.au=Chen%2C+I-Ming&rft.au=Hsu%2C+Fu-Fei&rft.au=Chen%2C+Yen-Hui&rft.date=2021-01-01&rft.pub=American+Heart+Association%2C+Inc&rft.issn=1079-5642&rft_id=info:doi/10.1161%2FATVBAHA.120.315398&rft.externalDocID=10.1161%2FATVBAHA.120.315398
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-5642&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-5642&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-5642&client=summon